GNCA Stock Plummets 97.4% on May 7, 2026 After Bankruptcy

GNCA stock has become one of the worst performers on NASDAQ, trading at just $0.0001 per share today. The biotech company, Genocea Biosciences, Inc., has lost 97.4% of its value, reflecting the severe financial distress following its Chapter 11 bankruptcy filing in July 2022. The Cambridge, Massachusetts-based cancer immunotherapy developer now trades at penny stock levels, with a market cap near zero. Investors who held shares through the company’s decline have seen devastating losses. Understanding GNCA stock’s collapse requires examining the company’s failed clinical programs and financial deterioration.

GNCA Stock Price Collapse and Trading Activity

GNCA stock trades at $0.0001 today, down sharply from its $1.45 year high. The stock has fallen 99.99% over the past decade, making it one of the market’s most distressed securities. Volume remains thin at 30,268 shares traded, well below the 80,568 average daily volume. The 50-day moving average sits at $0.004724, while the 200-day average is $0.11461935, both far above current levels.

This extreme decline reflects the company’s inability to advance its cancer immunotherapy pipeline. Track GNCA on Meyka for real-time updates on this penny stock. The previous close was $0.0039, showing continued downward pressure. With such low trading volume and minimal liquidity, GNCA stock presents significant risks for any investor considering entry.

Financial Metrics Show Severe Deterioration

Genocea Biosciences’ financial position has deteriorated dramatically. The company reports negative earnings per share and operates with substantial cash burn. Key metrics reveal a net profit margin of negative 9.4%, with operating losses consuming resources rapidly. Return on equity stands at negative 85.5%, indicating the company destroys shareholder value.

The company’s cash position of $0.54 per share provides limited runway. Free cash flow per share is negative $0.71, showing ongoing cash consumption. With 74 full-time employees and minimal revenue generation, the company continues burning through remaining capital. These metrics explain why GNCA stock has become essentially worthless in market valuation.

Pipeline Failure and Bankruptcy Impact

Genocea Biosciences developed two main cancer immunotherapy candidates: GEN-011 and GEN-009. Both programs remained in Phase 1/2a clinical trials when the company filed for Chapter 11 bankruptcy protection in July 2022. The company’s proprietary ATLAS platform, designed to identify patient-specific tumor neoantigens, failed to generate commercial success or sufficient investor confidence.

The bankruptcy filing marked the end of the company’s independent operations. Without successful clinical data or funding, the company could not continue development. This explains the catastrophic decline in GNCA stock value and the company’s transition to penny stock status. The failed immunotherapy approach and lack of alternative revenue sources sealed the company’s fate.

Market Sentiment and Liquidation Pressure

Trading activity in GNCA stock reflects extreme distress selling and liquidation. The relative volume of 0.38 indicates minimal interest from active traders. Most trading likely represents forced liquidation from bankruptcy proceedings or desperate shareholders exiting positions. The enterprise value of negative $26 million shows the company’s liabilities exceed assets significantly.

Meyka AI rates GNCA with a grade of C+, suggesting a HOLD rating based on fundamental analysis. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. However, this rating reflects the company’s pre-bankruptcy fundamentals and may not capture current bankruptcy realities. These grades are not guaranteed and we are not financial advisors.

Final Thoughts

GNCA stock’s 97.4% decline to $0.0001 reflects a complete collapse of shareholder value following Genocea Biosciences’ Chapter 11 bankruptcy filing. The company’s failed cancer immunotherapy pipeline, combined with severe cash burn and negative profitability metrics, left no path forward for recovery. With minimal trading volume and near-zero market capitalization, GNCA stock now trades as a penny stock with extreme risk. Investors should recognize this as a cautionary tale about biotech development risks and the importance of clinical trial success. The company’s situation demonstrates how quickly biotech valuations can evaporate when programs fail and funding dries up.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.